We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.54 | 0.16% | 960.175 | 960.33 | 960.93 | 967.88 | 957.10 | 967.88 | 191,163 | 19:48:48 |
From May 2019 to May 2024
By Cecilia Butini
Roche Holding AG said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued an opinion supporting the use of the REGN-COV2 antibody cocktail proposed for the treatment of Covid-19 patients.
The committee's opinion was produced as the European Medicines Agency carries out its rolling review process of the treatment, which is used to speed up the formal marketing application for the drug and which can be done during a public health emergency, Roche said. The cocktail is made of casirivimab and imdevimab, two monoclonal antibodies.
The Swiss pharma major is developing the antibody cocktail together with partner Regeneron Pharmaceuticals Inc, and the two companies plan to have more than two million doses available in 2021, Roche said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 26, 2021 07:50 ET (12:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
